Multiple Sclerosis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
For Healthy Volunteers:
Who might be able to join this trial:
- Men and women who are 18 years of age or older
- Non-smokers
- People with generally normal results on a standard medical check-up (any minor issues would be assessed by the doctor)
- People with normal eye health and no more than moderate prescription glasses or contact lenses (less than 6 Dpt)
Who may not be able to join:
- People who have been told they may possibly have multiple sclerosis (MS)
- People with a serious medical condition, as decided by the study doctor
- People with high blood pressure that is not being treated
- People who have a personal or family history of epilepsy
- People with any eye problems that would make reliable eye measurements impossible, as decided by the study doctor
- People with a family history of MS, optic neuritis, or a related condition called neuromyelitis optica (NMO or Devic disease)
- People who have had an inflammatory or infectious disease affecting the brain or spinal cord
- People whose best corrected vision (with glasses or contacts) is below a certain level
- People with a strong glasses or contact lens prescription (6 Dpt or more)
- People who are pregnant or planning to become pregnant
- People with alcohol dependency or substance abuse issues
For Patients with MS:
Who might be able to join this trial:
- Men and women who are 18 years of age or older
- People who have been diagnosed with relapsing-remitting multiple sclerosis (a form of MS with flare-ups and recovery periods) based on recognised medical criteria
- People who have had an episode of optic neuritis (inflammation of the eye nerve) in at least one eye, at least one year ago
- Non-smokers
- People with normal eye health and no more than a moderate glasses or contact lens prescription (less than 6 Dpt)
- People with good enough vision to take part in the eye blood flow measurements used in this study
- People whose other medications (not MS treatments) have been at a stable, unchanged dose for at least 30 days before joining, if the study doctor considers this relevant
Who may not be able to join:
- People with a serious medical condition other than MS, as decided by the study doctor
- People who have or have had neuromyelitis optica (NMO or Devic disease) or a related condition
- People who have had an inflammatory or infectious disease affecting the brain or spinal cord, other than MS
- People with high blood pressure that is not being treated
- People who have a personal or family history of epilepsy
- People with any eye problems that would make reliable eye measurements impossible, as decided by the study doctor
- People whose best corrected vision (with glasses or contacts) is below a certain level
- People with a strong glasses or contact lens prescription (6 Dpt or more)
- People who are pregnant or planning to become pregnant
- People with another significant neurological condition in addition to MS, if considered relevant by the study doctor
- People with alcohol dependency or substance abuse issues
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Gerhard Garhöfer, MD, Department of Clinical Pharmacology, Medical University of Vienna
Phone: 0043140400
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Flicker induced increase in retinal blood flow
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.